Drug Profile
Asparaginase Wolinella succinogenes-derived - Rare Disease Therapeutics
Alternative Names: Wolinella succinogenes-derived asparaginase; rWSLatest Information Update: 16 Jan 2022
Price :
$50
*
At a glance
- Originator Childrens Hospital Los Angeles
- Class Amidohydrolases; Antineoplastics
- Mechanism of Action Asparagine modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Precursor cell lymphoblastic leukaemia-lymphoma
Most Recent Events
- 29 Aug 2005 correspondence from RDT 26 Aug 2005. Rewrote intro slightly
- 21 Jun 2004 Phase-I/II clinical trials in Acute lymphoblastic leukaemia in USA (unspecified route)